+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2019

  • ID: 4769189
  • Drug Pipelines
  • 525 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • 4D Pharma Plc
  • Atlantic Healthcare Plc
  • Daiichi Sankyo Co Ltd
  • Gossamer Bio Inc
  • Naia Ltd
  • Redx Pharma Plc
  • MORE
Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2019, provides an overview of the Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline landscape.

Crohn’s disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn’s disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.

Report Highlights

This latest pipeline guide Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Crohn's Disease (Regional Enteritis) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 14, 30, 33, 1, 60, 19 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 3 and 2 molecules, respectively.

Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn's Disease (Regional Enteritis) (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Crohn's Disease (Regional Enteritis) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Crohn's Disease (Regional Enteritis) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Crohn's Disease (Regional Enteritis) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Crohn's Disease (Regional Enteritis) (Gastrointestinal)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Crohn's Disease (Regional Enteritis) (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Crohn's Disease (Regional Enteritis) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 4D Pharma Plc
  • Atlantic Healthcare Plc
  • Daiichi Sankyo Co Ltd
  • Gossamer Bio Inc
  • Naia Ltd
  • Redx Pharma Plc
  • MORE
Introduction

Crohn's Disease (Regional Enteritis) - Overview

Crohn's Disease (Regional Enteritis) - Therapeutics Development

Crohn's Disease (Regional Enteritis) - Therapeutics Assessment

Crohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics Development

Crohn's Disease (Regional Enteritis) - Drug Profiles

Crohn's Disease (Regional Enteritis) - Dormant Projects

Crohn's Disease (Regional Enteritis) - Discontinued Products

Crohn's Disease (Regional Enteritis) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by 4D Pharma Plc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by AbbVie Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Abivax SA, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by AlfaSigma SpA, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Allergan Plc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Alpha Cancer Technologies Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Alvotech ehf, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Amgen Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Anterogen Co Ltd, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Antibe Therapeutics Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Aptevo Therapeutics Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Arena Pharmaceuticals Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Artelo Biosciences Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Arven Ilac, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Atlantic Bio Sci LLC, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Atlantic Healthcare Plc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Avexegen Therapeutics Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Axim Biotechnologies Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by BioLingus AG, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Biond Biologics Ltd, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by BioXpress Therapeutics SA, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Boehringer Ingelheim GmbH, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Bristol-Myers Squibb Co, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Celgene Corp, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Celltrion Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Celularity Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by ChemoCentryx Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by ChironWells GmbH, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Commence Bio Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Concenter BioPharma Silkim Ltd, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Daiichi Sankyo Co Ltd, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by DBV Technologies SA, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by EA Pharma Co Ltd, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Eisai Co Ltd, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Eli Lilly and Co, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Enterome Bioscience SA, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Enzo Biochem Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by ETX Pharma Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Evelo Biosciences Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Ferring International Center SA, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by FYB202 GmbH & Co KG, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Galactica Biotech Ltd, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Galapagos NV, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Genentech Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by GlaxoSmithKline Plc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Gossamer Bio Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by IB Pharmaceuticals Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Inception Sciences Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by InDex Pharmaceuticals Holding AB, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by Innovation Pharmaceuticals Inc, H1 2019

Crohn's Disease (Regional Enteritis) - Pipeline by InSight Biopharmaceuticals Ltd, H1 2019

List of Figures

Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Top 10 Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 4D Pharma Plc
  • AbbVie Inc
  • Abivax SA
  • AlfaSigma SpA
  • Allergan Plc
  • Alpha Cancer Technologies Inc
  • Alvotech ehf
  • Amgen Inc
  • Anterogen Co Ltd
  • Antibe Therapeutics Inc
  • Aptevo Therapeutics Inc
  • Arena Pharmaceuticals Inc
  • Artelo Biosciences Inc
  • Arven Ilac
  • Atlantic Bio Sci LLC
  • Atlantic Healthcare Plc
  • Avexegen Therapeutics Inc
  • Axim Biotechnologies Inc
  • BioLingus AG
  • Biond Biologics Ltd
  • BioXpress Therapeutics SA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Celltrion Inc
  • Celularity Inc
  • ChemoCentryx Inc
  • ChironWells GmbH
  • Chong Kun Dang Pharmaceutical Corp
  • Commence Bio Inc
  • Concenter BioPharma Silkim Ltd
  • Daiichi Sankyo Co Ltd
  • DBV Technologies SA
  • EA Pharma Co Ltd
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Enterome Bioscience SA
  • Enzo Biochem Inc
  • ETX Pharma Inc
  • Evelo Biosciences Inc
  • Ferring International Center SA
  • FYB202 GmbH & Co KG
  • Galactica Biotech Ltd
  • Galapagos NV
  • Genentech Inc
  • GlaxoSmithKline Plc
  • Gossamer Bio Inc
  • IB Pharmaceuticals Inc
  • Inception Sciences Inc
  • InDex Pharmaceuticals Holding AB
  • Innovation Pharmaceuticals Inc
  • InSight Biopharmaceuticals Ltd
  • Inspyr Therapeutics Inc
  • JHL Biotech Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Jyant Technologies Inc
  • Kang Stem Biotech Co Ltd
  • Kashiv BioSciences LLC
  • Kyowa Hakko Kirin Co Ltd
  • Merck & Co Inc
  • Mesoblast Ltd
  • Metacrine Inc
  • Mitsubishi Tanabe Pharma Corp
  • Mycenax Biotech Inc
  • Naia Ltd
  • Nash Pharmaceuticals Inc
  • Nextbiotix SAS
  • Nichi-Iko Pharmaceutical Co Ltd
  • Nimbus Therapeutics LLC
  • Oncodesign SA
  • OSE Immunotherapeutics
  • Otsuka Holdings Co Ltd
  • Outlook Therapeutics Inc
  • PanTheryx Inc
  • Paradigm Biopharmaceuticals Ltd
  • Pfizer Inc
  • Protagonist Therapeutics Inc
  • Protheragen Inc
  • Provention Bio Inc
  • Qu Biologics Inc
  • Re-Pharm Ltd
  • RedHill Biopharma Ltd
  • Redx Pharma Plc
  • Saje Pharma LLC
  • Second Genome Inc
  • Seres Therapeutics Inc
  • Soligenix Inc
  • Synedgen Inc
  • Synlogic Inc
  • TaiwanJ Pharmaceuticals Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Tetherex Pharmaceuticals Corp
  • The Cell-Factory BVBA
  • Theravance Biopharma Inc
  • Thetis Pharmaceuticals LLC
  • Tiziana Life Sciences Plc
  • Ventria Bioscience
  • VHsquared Ltd
  • Xbrane Biopharma AB
Note: Product cover images may vary from those shown
Adroll
adroll